checkAd

    EQS-Adhoc  165  0 Kommentare HAEMATO AG: Termination of listing in the Open Market

    Für Sie zusammengefasst
    • HAEMATO AG terminates listing in Open Market
    • Shares will be discontinued on Frankfurt Stock Exchange
    • Shareholders can trade shares on Regulated Unofficial Market

    EQS-Ad-hoc: HAEMATO AG / Key word(s): Delisting
    HAEMATO AG: Termination of listing in the Open Market

    30-Nov-2023 / 14:14 CET/CEST
    Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.


    Berlin, November 30, 2023: The Management Board of HAEMATO AG ("Company"; ISIN: DE000A289VV1/ Open Market / Basic Board) has decided today, November 30, 2023, with the approval of the Supervisory Board, to terminate the inclusion of the Company's shares in the Open Market (Basic Board) on the Frankfurt Stock Exchange pursuant to Section 30 of the General Terms and Conditions of Deutsche Börse AG for the Open Market on the Frankfurt Stock Exchange (so-called delisting). The Management Board of the company will therefore send a corresponding letter of termination to Deutsche Börse AG today, November 30, 2023.
    Upon expiry of the notice period, which is three months and thus ends at the end of February 2024 at the latest, trading of the company's shares on the Open Market (Basic Board) of the Frankfurt Stock Exchange will be discontinued. Until the end of the three-month period, the company's shareholders will continue to have the opportunity to trade their shares on the Regulated Unofficial Market of the Frankfurt Stock Exchange. The company's shares will no longer be traded on another stock exchange at the company's instigation after their inclusion in the open market of the Frankfurt Stock Exchange has ended.

    About HAEMATO:
    HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on the trading of high-priced specialty pharmaceutical drugs (with a therapeutic emphasis on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". Further information can be found at https://haemato.de.



    Contact:
    HAEMATO AG, Investor Relations
    Telefon: +49 (0)30 897 30 86 70
    ir@haemato.ag


    End of Inside Information

    30-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.eqs-news.com


    Language: English
    Company: HAEMATO AG
    Lilienthalstraße 5c
    12529 Schönefeld
    Germany
    Phone: +49 (0)30 897 30 86 70
    Fax: +49 (0)30 897 30 86 79
    E-mail: ir@haemato.ag
    Internet: www.haemato.ag
    ISIN: DE000A289VV1
    WKN: A289VV
    Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Munich, Stuttgart, Tradegate Exchange
    EQS News ID: 1785693

     
    End of Announcement EQS News Service

    1785693  30-Nov-2023 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1785693&application_name=news&site_id=wallstreet

    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-Adhoc HAEMATO AG: Termination of listing in the Open Market EQS-Ad-hoc: HAEMATO AG / Key word(s): Delisting HAEMATO AG: Termination of listing in the Open Market 30-Nov-2023 / 14:14 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS …